HCPLive

Long-Acting Clotting Agent Approved for Form of Hemophilia

MONDAY, March 31, 2014 (HealthDay News) -- The drug Alprolix has been approved by the US Food and Drug Administration (FDA) as the first long-acting hemophilia B clotting agent, the FDA said in a news release.

The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first hemophilia B remedy designed to require less frequent injections than prior treatments, the FDA said. It was approved to help control and prevent bleeding episodes and to manage bleeding during surgery.

Alprolix was evaluated in clinical studies involving 123 people, ages 12-71, with severe hemophilia B. No safety issues were identified during the trials, the FDA said.

The product is manufactured by Biogen Idec, located in Cambridge, Mass.

More Information


Copyright © 2014 HealthDay. All rights reserved.

Most Popular

Recommended Reading

The US had been found to have a higher percentage of opioid use than in any other country.
While children with HIV may have low levels of a key immune cell, a new study shows that most will recover the cell with proper treatment.
Patients administered minimally invasive surgery (MIS) colon resection procedures instead of open surgery leave the hospital quicker and require less follow up with physicians and fewer medical prescriptions.
Although the relationship between pain and spatial representation is unclear, a study published in Current Biology took steps in understanding how pain is activated in the brain and raised the possibility of reducing the sensation.
$vAR$